secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2026-09-23T11:30:41+00:00
Accession:  0001104659-26-109814
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents regains Nasdaq bid price compliance; MVLS delisting risk remains
-----------------------------------------------------------------------------

- Regained compliance with Nasdaq Rule 5550(a)(2) after closing bid price held ≥$1.00 for 10 sessions ending Sept 21, 2026.
- Still non-compliant with Rule 5550(b)(2) MVLS requirement: market value below $35M minimum; deadline Dec 28, 2026.
- Company evaluating options, including raising stockholders' equity to at least $2.5M, to satisfy MVLS before deadline.
- CEO reiterates priorities: operating cash flow breakeven in H2 2026, advancing DrugSorb-ATR toward FDA approval.
- No assurance of regaining MVLS compliance or maintaining Nasdaq listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/0001104659-26-109814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/tm2625982d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-109814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer